UNSPSC 51281820: Esorubicin hydrochloride

This classification denotes an anthracycline antibiotic C27H29NO10.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2UB1JJT82D, chemically known as (8s,10s)-10-(((2s,4r,6s)-4-aminotetrahydro-6-methyl-2h-pyran-2-yl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione hydrochloride, but more generally known as esorubicin hydrochloride, which bears US NIH Compound Identifier 152035. Most nations, for tariff and trade purposes, schedule esorubicin hydrochloride under HS 29419000 and SITC 54139.

As of Q4 2014, ESORUBICIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Esorubicin hydrochloride bears US NLM identifiers UMLS ID C2700018 and NCI Concept Code C74943. SMILES: C[C@H]1C[C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3C2C(C4C(C3O)C(=O)C5CCCC(C5C4=O)OC)O)(C(=O)CO)O)N.CL.

UNSPSC 51281820 Esorubicin hydrochloride is a Commodity code for a specific pharmaceutical active ingredient, but the recent state and local opportunities posted under this code do not reflect procurement of esorubicin. Instead, the tagged solicitations document purchases of entirely different drugs — doxycycline hyclate, ciprofloxacin hydrochloride, and naloxone — indicating a mismatch between the code assignment and the work actually being bought. State and local health agencies and county health departments use this code space to procure pharmaceuticals through piggyback agreements with established consortiums and through competitive sealed bidding, typically in bulk quantities with multi-year terms and renewal options.

Recent activity appears concentrated in the Southeast. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 for antibiotic pharmaceuticals with a 12-month initial term and renewal options; Seminole County, Florida released an IFB on June 30, 2026 for naloxone and drug deactivation systems with quarterly deliveries and a two-year initial term. The code shows limited recent relevant activity aligned with esorubicin procurement, and business development professionals should verify current pharmaceutical procurement practices directly with target health departments rather than rely on this code's recent tagged opportunities.